Nanoform Finland has announced a pre-clinical development agreement with the plasma-derived therapies business unit of Takeda to develop new formulations for the treatment of rare conditions. This collaboration will leverage Nanoform’s nanoforming technology to enhance the performance of plasma-derived therapies.
Crown Laboratories Inc., a privately held skincare company, has entered into a merger agreement with Revance Therapeutics, Inc., a biotechnology firm known for its aesthetic and therapeutic products. Under the terms of the agreement, Crown will acquire all outstanding shares
ViroCell Biologics has successfully completed an oversubscribed convertible note offering, aimed at driving the company’s growth in the cell and gene therapy (CGT) sector. The funding round was led by new investor First Light Asset Management LLC, with participation from
“Building mutual understanding and trust is the foundation for optimising performance and driving innovation with contract manufacturing organisations (CMOs),” says Guosheng Zhao, Senior External Manufacturing Lead at LEO Pharma. Guosheng Zhao brings years of experience in procurement, management consulting at
LSPedia, a global provider of product traceability SaaS solutions, has announced a strategic partnership with Pharma Logistics, a company specializing in pharmaceutical reverse distribution. This collaboration is focused on delivering enhanced compliance, data visibility, and supply chain efficiency for their
Evonik is partnering with KNAUER Wissenschaftliche Geräte GmbH to enhance the scale-up process for lipid nanoparticle (LNP) formulations. The collaboration aims to improve efficiency and speed up the transition from small-scale prototypes to production-scale formulations, reducing preclinical development time. The
CiVentiChem, a Contract Development and Manufacturing Organization (CDMO), has completed a new facility that significantly increases its manufacturing capacity by 300%. This expansion is aimed at producing Regulatory Starting Materials (RSMs) and intermediates, supporting both small molecule clinical and commercial
Champalimaud Foundation, a biomedical clinical research organization, has implemented Lonza’s MODA-ES® Platform at its Clinical Centre in Lisbon, Portugal. This strategic move is set to streamline the manufacturing of cell therapies, particularly for patients with cancer who have unmet medical
Taiwan Bio Therapeutics, Inc. and TRACT Therapeutics, Inc. have achieved a key milestone with the successful transfer of TRACT’s TregCel platform technology to Taiwan Bio’s GMP cell manufacturing facility. The partnership, established in December 2023, combines Taiwan Bio’s expertise in
Ritedose, a CDMO specializing in sterile Blow Fill Seal (BFS) production, has announced a substantial increase in its annual donation to Dispensary of Hope, a nonprofit organization dedicated to providing essential medications to low-income and chronically ill patients. This year,
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
